PatientsVille.com LogoPatientsVille.com

Dyspepsia | Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital

Dyspepsia research study

What is the primary objective of this study?

Peptic ulcer disease is the most common gastrointestinal disease. Antibiotic resistant Helicobacter pylori is a major problem worldwide. The gold standard for Helicobacter pylori eradication is composed of Proton-pump inhibitor/Ranitidine bismuth citrate + Amoxycillin + Metronidazole /Clarithromycin. In Thailand, clarithromycin resistant strains increased and led to treatment failure. Data on file at Rajavithi Hospital showed that metronidazole resistant H. pylori was about 50% and Clarithromycin resistant strains accounted for 8%. This molecular genetic study will be performed in patients presenting with dyspepsia, who had an indication for gastroscopic examination, to explore the incidence of antibiotic resistant Helicobacter pylori in Rajavithi Hospital, Thailand.

Who is eligible to participate?

Inclusion Criteria: - male or female with dyspepsia - age > 15 years - fulfil indication for gastroscopic examination - able to give informed consent Exclusion Criteria: - contraindication for gastroscopic examination and biopsy

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Dyspepsia

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Procedure:gastroscopic examinationgastroscopic examination for tissue biopsy and real time PCR for gene study

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

1Gastroscope positive for H. pylori and resistant to clarithromycin

2Gastroscope positive for H. pylori and not resistant to clarithromycin

Study Status

Unknown status

Start Date: June 2006

Completed Date: December 2008

Phase: Phase 3

Type: Observational

Design:

Primary Outcome: Incidence of H. pylori Clarithromycin resistance gene

Secondary Outcome: Characteristic of H. pylori clarithromycin resistant gene mutation

Study sponsors, principal investigator, and references

Principal Investigator: Piyathida Harnsoomboon, MD

Lead Sponsor: Rajavithi Hospital

Collaborator:

More information:https://clinicaltrials.gov/show/NCT00285688

Discuss Ranitidine